Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

16.50USD
26 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$16.50
Open
$16.45
Day's High
$16.60
Day's Low
$16.05
Volume
1,001,714
Avg. Vol
1,019,640
52-wk High
$33.00
52-wk Low
$15.60

Latest Key Developments (Source: Significant Developments)

Acorda Therapeutics to cut 20 pct of workforce
Wednesday, 5 Apr 2017 06:00am EDT 

Acorda Therapeutics Inc : Acorda Therapeutics implements corporate restructuring . Acorda Therapeutics says corporate restructuring to reduce cost structure and focus resources on two late-stage programs, CVT-301 and Tozadenant . Acorda Therapeutics says as part of restructuring, co is reducing headcount by about 20 percent . Acorda Therapeutics says co expects to realize estimated annualized cost savings from reduction in personnel of about $21 million beginning in Q2 of 2017 . Acorda Therapeutics says estimates that it will incur about $7.6 million of pre-tax charges for severance and other costs related to restructuring . Acorda Therapeutics says co plans to file a new drug application for CVT-301 with the FDA in the second quarter of 2017 .Acorda - adoption of restructuring plan follows invalidation of certain patents pertaining to Ampyra (dalfampridine) extended release tablets, 10 mg.  Full Article

U.S. district court invalidates four Acorda Therapeutics Ampyra patents
Friday, 31 Mar 2017 12:31pm EDT 

Acorda Therapeutics Inc : U.S. district court issues decision to invalidate four Ampyra patents; company will appeal ruling .Company has developed contingency plans to address its business needs and objectives in event of a loss of Ampyra exclusivity.  Full Article

Acorda announces long-term safety data for CVT-301
Wednesday, 29 Mar 2017 06:00am EDT 

Acorda Therapeutics Inc : Acorda announces long-term safety data for cvt-301 . New drug application (NDA) submission planned by end Q2 2017 . Plans to file a marketing authorization application (MAA) in europe by end of 2017 . Pulmonary function measures over 12 months comparable between CVT-301 and observational control group .Acorda therapeutics - there was one death in study, a drowning in CVT-301 84 MG group, judged by investigator to be not related to study drug.  Full Article

Scopia Capital Management reports 12 pct passive stake in Acorda Therapeutics
Friday, 10 Mar 2017 04:59pm EST 

Scopia Capital Management LP: Scopia Capital Management LP reports 12 percent passive stake in Acorda Therapeutics Inc as of Feb 28 - SEC filing .Scopia Capital Management LP - previously reported a 9.8 percent passive stake in Acorda Therapeutics as of Dec 31, 2016.  Full Article

Acorda Therapeutics entered into settlement agreement with Apotex Corp, Apotex Inc on Feb. 8
Friday, 10 Feb 2017 07:57am EST 

Acorda Therapeutics Inc : Acorda Therapeutics Inc - on Feb 8, 2017, Acorda Therapeutics, inc entered into settlement agreement with Apotex Corporation and Apotex Inc-sec filing . Acorda Therapeutics- as result of settlement agreement, co will be permitted to market generic version of ampyra in united states at specified date in 2025 . Acorda Therapeutics Inc - settlement to resolve pending patent litigation brought by company against Apotex involving ampyra extended-release tablets . Acorda Therapeutics - parties will request court enter consent order, in which it will dismiss company's litigation against apotex referred to above .Acorda Therapeutics Inc - details of settlement are confidential.  Full Article

Acorda announces 2016 AMPYRA net sales and 2017 financial guidance
Monday, 9 Jan 2017 06:00am EST 

Acorda Therapeutics Inc : Acorda announces 2016 AMPYRA net sales and 2017 financial guidance at J.P. Morgan healthcare conference . Sees FY 2017 sales $535 million to $545 million . Q4 sales $132 million versus I/B/E/S view $137.5 million . Acorda Therapeutics - continue to enroll Phase 3 study of tozadenant in people with parkinson's and expect topline data from study in Q1 of 2018 . Acorda Therapeutics Inc - at year-end 2016, company projects cash, cash equivalents and investments of approximately $155 million (unaudited) .Acorda Therapeutics - on track to announce topline data from CVT-301 phase 3 efficacy,long-term safety trials for treatment of off periods in parkinson's.  Full Article

Acorda Therapeutics Q3 non-GAAP loss per share $0.04
Thursday, 27 Oct 2016 06:00am EDT 

Acorda Therapeutics Inc : Acorda provides financial and pipeline update for third quarter 2016 . Q3 non-GAAP loss per share $0.04 . Q3 GAAP loss per share $0.28 . Q3 revenue $128.8 million versus I/B/E/S view $134 million . Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S .Acorda Therapeutics inc - company is reiterating 2016 Ampyra net sales guidance of $475-$485 million.  Full Article

Arbitral Tribunal confirms Acorda's redemption right regarding Biotie shares
Monday, 26 Sep 2016 02:30am EDT 

Biotie Therapies Oyj : Arbitral Tribunal confirmed Acorda's redemption right regarding Biotie shares .Biotie shares trading has been terminated.  Full Article

Acorda Therapeutics says on June 1 entered credit agreement with units - SEC filing
Thursday, 2 Jun 2016 07:53am EDT 

Acorda Therapeutics Inc : On June 1, co, units entered into a credit agreement - SEC filing . Initial availability under facility is approximately $58 million. .Agreement provides company with a three-year senior secured revolving credit facility in maximum amount of $60 million.  Full Article

Biotie Therapies announces final results of subsequent offer period of Acorda Therapeutics tender offer
Monday, 2 May 2016 09:40am EDT 

Biotie Therapies Oyj:Final results of the subsequent offer period of Acorda Therapeutics tender offer for all securities in Biotie.38.4 million shares and 58,121 American Depositary Shares (ADSs) were tendered during subsequent offer period.Together with other equity interests tendered in tender offer during initial offer period, about 97.36 percent of all shares and votes were tendered.  Full Article

More From Around the Web

Acorda Therapeutics to cut 20 percent of workforce

Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.